- | Renovacor
Physics To Genetics: New Treatments For Hereditary Heart Disease
“Renovacor is in a similar situation to the one MyoKardia was in five years ago,” says Dr. Semigran. “We have knowledge of the mechanism of action of dilated cardiomyopathy, where there’s an inadequate amount of a required protein for the heart muscle to function correctly. And fortunately, I think the field of selective gene therapy for the heart has evolved to the point that we’ve got a pretty good chance of targeting the underlying abnormality of the segment of the cardiomyopathy population with a BAG3-associated condition.”
- | Scynexis
Can Ibrexafungerp Treat Candida Auris?
The therapy was developed by Jersey City, New Jersey-based biotechnology company, Scynexis. The company has also been studying ibrexafungerp in its CARES study in hospitalized patients with C. auris.
- | Anima Biotech
Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says
“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.
- | Palisade Bio
Episode 21-29 Reverse engineering success ???
Moira speaks with psychologist Dr. Ron Friedman about “Decoding Greatness … How the Best in the World Reverse Engineer Success”. Then Dr. Tom Hallam from Palisade Bio in San Diego talks about their efforts to solve a major problem post-surgery – how to get your GI track back on track. And Tech Nation Health Chief Correspondent Dr. Daniel Kraft reviews tests to detect Alzheimer’s early.
- | TFF Pharmaceuticals
EPR Podcast Episode 3 – Inhaled and intranasal drug formulations and delivery – Dr Bill Williams, University of Texas
Bill then discussed some of the current applications of the TFF technology – including enhancing the stability of Takeda Vaccine’s norovirus vaccine. “We laid out the premise that in the liquid form, or even the frozen form, that the antigen was losing activity… but in the paper we showed that through TFF this norovirus vaccine could be stabilised – we are up to several months at 40°C,” he enthused, an amazing achievement since most vaccines require cold chain storage and Pfizer and BioNTech’s mRNA COVID-19 vaccine required ultra-low refrigeration (-70°C or -80°C) to be distributed originally.
- | Araris Biotech
Industry Taking Notice of Araris Biotech’s Linker Technology for ADC Delivery
Swiss pharma company Araris Biotech AG is attracting attention based on ongoing research with its linker technology for antibody drug conjugate delivery. The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
- | Leyden Labs
Developing Nasal Sprays for Temporary Protection Against Existing and New Respiratory Viruses with Koenraad Wiedhaup Leyden Labs
Koenraad Wiedhaup, Founder and CEO of Leyden Labs, and his team have taken a proactive approach to overcome the challenges of protecting people from known viruses and new viruses. They are developing intranasal sprays containing biological molecules that can temporarily protect against a broad range of viruses. This approach is between a vaccine that often gives long-term protection and a therapeutic necessary once someone is infected.
- | Heat Biologics
Evidence Building for a Mix and Match Approach to COVID-19 Vaccines
Heat Biologics, still have the potential to play a big role in ending the pandemic.
